Бойцов С.А. Профилактика неинфекционных заболеваний в стране: от «что делать» к «как делать». Профилактическая медицина. 2012;2:3-10.
Барбараш О.Л., Кашталап В.В. Роль фармакоинвазивной тактики ведения пациентов с острым коронарным синдромом с подъемом сегмента ST в России. Кардиология. 2014;54(9):79-85.
Барбараш О.Л. Европейская программа «Stent for life»: предпосылки, история создания, основные цели и задачи. Комплексные проблемы сердечно-сосудистых заболеваний. 2013;1:10-18.
Эрлих А.Д. Двойная антитромбоцитарная терапия: необходимость приверженности лечению и возможности ее повышения. Атеротромбоз. 2014;2:25-33.
Барбараш О.Л., Каретникова В.Н., Кашталап В.В. Пациент после инфаркта миокарда: как снизить риск повторного ишемического события? Кардиосоматика. 2015;6(2):12-19.
2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal Advance Access published August 29, 2015. European Heart Journal. doi:10.1093/ eurheartj/ehv320..
DOI: 10.1093/ eurheartj/ehv320
2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal Advance Access published August 29, 2014. European Heart Journal doi:10.1093/ eurheartj/ehu278..
DOI: 10.1093/ eurheartj/ehu278
The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
Yusuf S., Mehta S.R., Zhao F. еt al. For the CURE Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation. 2003;107:966-972.
Steinhubl S.R., Berger P.B., Mann J.T.3rd. et al. For CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-2420.
Wallentin L., Becker R.C., Budaj A. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–57.
Lindholm D., Varenhorst C., Cannon C.P. et al. Ticagrelor vs. clopidogrel in patients with non ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal. 2014;35:2083–2093.
Барбараш О.Л., Кашталап В.В. Первый опыт использования тикагрелора в России. Consilium medicum. 2012;14(10):32-35.
Bonaca M.P., Bhatt D., Cohen M. et al. for the PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015. doi: 10.1056/NEJMoa1500857..
DOI: 10.1056/NEJMoa1500857
Jernberg T., Hasvold P., Henriksson M., Hjelm H., Thuresson M., Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. Eur Heart J. doi: 10.1093/eurheartj/ehu505..
DOI: 10.1093/eurheartj/ehu505
Price M.J. The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. Am Coll Cardiol. 2015;65(13):1311-1313.
Сutlip D.E., Kereiakes D.J., Mauri L. et al. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. J Am Coll Cardiol Interv. 2015;8:404410.
Эрлих А.Д. от имени всех участников регистра РЕКОРД-3. 12-месячные исходы у пациентов с острым коронарным синдромом, включенных в Российский регистр РЕКОРД-3. Российский кардиологический журнал. 2018;3(155):23-30. http://dx.doi. org/10.15829/1560-4071-2018-3-23-3..
DOI: 10.15829/1560-4071-2018-3-23-3
Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ИБС в реальной клинической практике по данным регистра ПРОГНОЗ ИБС (часть 2). Рациональная фармакотерапия в кардиологии. 2013;9(5):494-499.
McFadden E.P., Stabile E., Regar E., Cheneau E., Ong A.T.L., Kinnaird T., Suddath W.O., Weissman N.J., Torguson R., Kent K.M., Pichard A.D., Satler L.F., Waksman R., Serruys P.W. Late thrombosis in Drug-Eluting Coronary Stents discontinuation of antiplatelet therapy. Lancet. 2004;364:1519-21.
Schulz S., Schuster T., Mehilli J., Byrne R.A., Ellert J., Massberg S., Goedel J., Bruskina O., Ulm K., Schomig A., Kastrati A. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. European Heart Journal. 2009;30:2714-2721. doi:10.1093/eurheartj/ehp275..
DOI: 10.1093/eurheartj/ehp275
Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376162 patients. The American Journal of Medicine. 2012;9(125):882887.
Becker R.C., Meade T.W., Berger P.B. et al. American College of chest physicians. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (8-th Edition). Chest. 2008;133(6 Suppl):776S-814.
Garcia Rodriguez L.A., Patrignani P., GonzalezPerez A. Risk of myocardial infarction persisting after discontinuation of nonsteroidal antiinflammatory drugs in the general population. J Thromb Haemost. 2009;7:892-894.
Горбунов В.М. Проблемы приверженности больных, перенесших инфаркт миокарда, профилактическому приему ацетилсалициловой кислоты. Результаты исследования ACT. Кардиоваскулярная терапия и профилактика. 2010;9(5):1-7.
Molife C., Frech-Tamas F., DeKoven M., Effron M.B., Karkare S., Zhu Y., Larmore C., Lu J., McCollam P., Marrett E., Vetrovec G.W. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor. J Med Econ. 2015;18:898-908.
Schmitt J. et al Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J. 2009;30:1038-1045.
Kralev S., Schneider K., Lang S., Suselbeck T., Borggrefe M. Incidence and Severity of Coronary Artery Disease in Patients with Atrial Fibrillation Undergoing First-Time Coronary Angiography. PLoS ONE. 2011;6(9):e24964. doi:10.1371/journal.pone.0024964..
DOI: 10.1371/journal.pone.0024964
Rahman F., Kwan G.F., Benjamin E.J. Global epidemiology of atrial fibrillation. Nature Reviews Cardiology. 2014;11:639-654. doi:10.1038/nrcardio.2014.118..
DOI: 10.1038/nrcardio.2014.118
Bang C.N., Gislason G.H., Greve A.M., Bang C.A. et al. New-Onset Atrial Fibrillation is Associated With Cardiovascular Events Leading to Death in a First Time Myocardial Infarction Population of 89 703 Patients With Long-Term Follow-Up: A Nationwide Study. J Am Heart Assoc. 2014;3:e000382 doi: 10.1161/ JAHA.113.000382..
DOI: 10.1161/ JAHA.113.000382
Rene A.G., Généreux P., Ezekowitz M. et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am. J. Cardiol. 2014;113:236-242.
Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969974.
Lamberts M. et al. Bleeding After Initiation of Multiple Antithrombotic Drugs, Including Triple Therapy, in Atrial Fibrillation Patients Following Myocardial Infarction and Coronary Intervention Circulation. 2012;126:1185-1193.
Potpara T.S., Lane D.A., Lip G.Y.H. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace. 2015;17(4):507-508.
Dewilde W.J., Oirbans T., Verheugt F.W., Kelder J.C., De Smet B.J., Herrman J.P., Adriaenssens T., Vrolix M., Heestermans A.A., Vis M.M., Tijsen J.G., van ‘t Hof A.W., ten Berg J.M.; WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):11071115. doi: 10.1016/S0140-6736(12)62177-1..
DOI: 10.1016/S0140-6736(12)62177-1
Lip G. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). European Heart Journal. 2014. doi:10.1093/eurheartj/ehu298..
DOI: 10.1093/eurheartj/ehu298
Cannon C.P., Gropper S., Bhatt D.L., Ellis S.G., Kimura T., Lip G.Y., Steg P.G., Ten Berg J.M., Manassie J., Kreuzer J., Blatchford J., Massaro J.M., Brueckmann M., Ferreiros Ripoll E., Oldgren J., Hohnloser S.H.; RE-DUAL PCI Steering Committee and Investigators. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. Clin Cardiol. 2016 Oct;39(10):555-564. doi: 10.1002/clc.22572. Epub 2016 Aug 26..
DOI: 10.1002/clc.22572. Epub 2016 Aug 26
Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A. et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2018;39:213–254. doi:10.1093/eurheartj/ ehx419..
DOI: 10.1093/eurheartj/ ehx419
Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
Gibson C.M., Pinto D.S., Chi G., Arbetter D., Yee M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P., Burton P., van Eickels M., Korjian S., Daaboul Y., Jain P., Lip G.Y., Cohen M., Peterson E.D., Fox K.A. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy. Circulation. 2017 Jan 24;135(4):323-333. doi: 10.1161/ CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Erratum in: Circulation. 2017 Mar 21;135(12):e789..
DOI: 10.1161/ CIRCULATIONAHA.116.025783. Epub 2016 Nov 14. Erratum in: Circulation. 2017 Mar 21;135(12):e789
Кашталап В.В., Барбараш О.Л. Актуальные проблемы антитромботической терапии при остром коронарном синдроме (по материалам Европейского конгресса кардиологов 2017). Медицинский совет. 2017;12:82-88. 10.21518/2079-701X-2017-12-82-88.